Novoheart Holdings


Novoheart is a global stem cell biotechnology company dedicated to engineering bioartificial human heart surrogates using state-of-the-art bioengineering approaches. Their mission is to revolutionize drug discovery and the development of heart therapeutics with superior safety and efficacy, and to develop transplantable grafts for regenerative heart therapies. They have a long history in human cardiac tissue engineering, with a comprehensive platform and the only Human-Heart-in-a-Jar. They focus on creating advanced human cardiac models for disease modeling, drug screening, and therapeutic development, aiming to reduce costs, time, and improve safety and efficacy in heart disease research.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

medium (51-250)

Novoheart Holdings

6 Tide Street, 2nd Floor, Boston, MA 02210, USA


Products

Ventricular cardiomyocyte differentiation kits and cell media

Kits and maintenance media for generating and maintaining ventricular-like cardiomyocytes from pluripotent stem cells.

3D cardiac tissue strip assay kits and consumables

Kits, cartridges and multi-well plate formats for fabricating 3-D contractile tissue strips and performing contractility assays in bioreactors.

Anisotropic cardiac sheet assay kits and patterned substrates

Fabrication kits and micropatterned substrates for aligned monolayer assays to assess conduction and pro-arrhythmic risk.

Cardiac organoid chamber kits and consumables

Kits and molds for generating fluid-ejecting ventricular organoid chambers and supporting consumables for pump-function assays.

Instruments and software suites for tissue assays

Instrument systems for assay automation and monitoring combined with software modules for data acquisition, processing and analysis across contractility, electrophysiology and organoid assays.


Services

Design and execution of disease-specific assays and compound testing using engineered human cardiac tissues; includes experimental design, milestone reporting and data delivery.

Supply of healthy and disease human ventricular cardiomyocytes and differentiation of customer iPSC/hESC lines for tissue fabrication.

Generate validated preclinical data from human tissue models and provide documentation to support regulatory filings and investigational new drug applications.

Training programs and protocol transfer to enable customers to fabricate tissues and operate instrument systems independently.

Scientific consultation and partnership development for bespoke programs, including co-development with industry partners.

Expertise Areas

  • Cardiac tissue engineering
  • Human pluripotent stem cell differentiation and cell supply
  • In vitro electrophysiology and arrhythmia modeling
  • Contractility assays and force measurement
  • Show More (6)

Key Technologies

  • Human pluripotent stem cell (hPSC) differentiation
  • 3D engineered cardiac tissues
  • Cardiac organoid chambers with pressure-volume readouts
  • Microgrooved / micropatterned substrates for anisotropy
  • Show More (6)

News & Updates

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.